Cargando…
Hydrocortisone to treat early bronchopulmonary dysplasia in very preterm infants: study protocol for a randomized controlled trial
BACKGROUND: Bronchopulmonary dysplasia (BPD) is still a common complication in very premature infants. At present, there is no effective treatment for BPD. Glucocorticoids are drugs commonly used to prevent or treat BPD before and after birth. In very premature infants with high risk factors for BPD...
Autores principales: | He, Yuan, Zhang, Yong, Gao, Shuqiang, Wang, Xiaoling, He, Na, Zhang, Deshuang, Dong, Wenbin, Wieg, Christian, Lei, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469331/ https://www.ncbi.nlm.nih.gov/pubmed/32883333 http://dx.doi.org/10.1186/s13063-020-04698-0 |
Ejemplares similares
-
The application value of lung ultrasound findings in preterm infants with bronchopulmonary dysplasia
por: Gao, Shuqiang, et al.
Publicado: (2020) -
Evidence for the Management of Bronchopulmonary Dysplasia in Very Preterm Infants
por: Muehlbacher, Tobias, et al.
Publicado: (2021) -
Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial
por: Onland, Wes, et al.
Publicado: (2011) -
Platelet is the early predictor of bronchopulmonary dysplasia in very premature infants: an observational cohort study
por: Wang, Xiaoling, et al.
Publicado: (2022) -
Hydrocortisone and bronchopulmonary dysplasia: variables associated with response in premature infants
por: Clauss, Christie, et al.
Publicado: (2020)